Global Enrollment Starts for Phase 3b Trial of Oral Edaravone

Global Enrollment Starts for Phase 3b Trial of Oral Edaravone

309437

Global Enrollment Starts for Phase 3b Trial of Oral Edaravone

A Phase 3b clinical trial is recruiting adults with amyotrophic lateral sclerosis (ALS) to compare the safety and efficacy of two dosing regimens of oral edaravone versus a placebo. The trial (NCT04569084), sponsored by Mitsubishi Tanabe Pharma America, the therapy’s developer, seeks to enroll 380 ALS patients (age 18 to 75), whose first symptoms developed in the two years prior to enrollment, according to a press release from the Muscular Dystrophy Association. Recruitment will take place…

You must be logged in to read/download the full post.